Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
MiNK Therapeutics (INKT)
NASDAQ:INKT
MiNK Therapeutics (INKT) Stock Price & Analysis
90 Followers
INKT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.75 - $3.34
Previous Close$0.95
Volume40.32K
Average Volume (3M)101.19K
Market Cap
$33.05M
Enterprise Value$29.65M
Total Cash (Recent Filing)$3.40M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-1.5
Beta1.32
Next Earnings
May 14, 2024EPS Estimate
-$0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding34,699,056
10 Day Avg. Volume50,362
30 Day Avg. Volume101,195
Standard Deviation0.26
R-Squared0.00004
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)-1.90
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.81
Forecast
1Y Price Target
$8.50Price Target Upside776.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
MiNK Therapeutics News
Ownership Overview
71.57% Insiders
1.26% Mutual Funds
1.19% Other Institutional Investors
25.98% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
INKT FAQ
What was MiNK Therapeutics’s price range in the past 12 months?
MiNK Therapeutics lowest stock price was $0.75 and its highest was $3.34 in the past 12 months.
What is MiNK Therapeutics’s market cap?
Currently, no data Available
When is MiNK Therapeutics’s upcoming earnings report date?
MiNK Therapeutics’s upcoming earnings report date is May 14, 2024 which is in 5 days.
How were MiNK Therapeutics’s earnings last quarter?
MiNK Therapeutics released its earnings results on Mar 21, 2024. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.152 by -$0.008.
Is MiNK Therapeutics overvalued?
According to Wall Street analysts MiNK Therapeutics’s price is currently Undervalued.
Does MiNK Therapeutics pay dividends?
MiNK Therapeutics does not currently pay dividends.
What is MiNK Therapeutics’s EPS estimate?
MiNK Therapeutics’s EPS estimate is -$0.15.
How many shares outstanding does MiNK Therapeutics have?
MiNK Therapeutics has 34,699,055 shares outstanding.
What happened to MiNK Therapeutics’s price movement after its last earnings report?
MiNK Therapeutics reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.152. Following the earnings report the stock price went down -1.111%.
Which hedge fund is a major shareholder of MiNK Therapeutics?
Among the largest hedge funds holding MiNK Therapeutics’s share is Oracle Investment Management Inc. It holds MiNK Therapeutics’s shares valued at 39K.
---
MiNK Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.50 (776.83% Upside)
$8.50 (776.83% Upside)
Crowd Wisdom
Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.66%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-78.80%
Trailing 12-Months
Company Description
MiNK Therapeutics
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other life-threatening illnesses.
---
INKT Earnings Call
Q4 2024
0:00 / 0:00
---
INKT Stock 12 Month Forecast
Average Price Target
$8.50
▲(776.83% Upside)
Technical Analysis
Apellis Pharmaceuticals
―
Crispr Therapeutics AG
―
Editas Medicine
―
Genetic Technologies
―
Best Analysts Covering INKT
1 Year
1 Year Success Rate
2/7 ratings generated profit
1 Year Average Return
-27.26%
assigned a buy rating 2 months ago
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -27.26% per trade.
---